mardi 29 avril 2014

Immunogenic mutations in tumor genomes correlate with increased patient survival

Developing immunotherapies for cancer is challenging because of significant variability among tumors and diversity in human immune types. In a new study, researchers examined the largest collection of tumor samples to date to predict patient-specific tumor mutations that may activate the patient's immune system, paving the way for more successful, personalized cancer immunotherapy. Immunogenic mutations in tumor genomes correlate with increased patient survival

Aucun commentaire:

Enregistrer un commentaire